1-2 of 2
Steve Lo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Matthew S. Davids, Christine E. Ryan, Yue Ren, Liam Hackett, Jeremy Zhang, Svitlana Tyekucheva, Stacey M. Fernandes, Jennifer L. Crombie, Austin I. Kim, Matthew Weinstock, Josie Montegaard, Heather A. Walker, Claire Greenman, Victoria Patterson, Caron A. Jacobson, Ann S. LaCasce, Philippe Armand, David C. Fisher, Steve Lo, Adam J. Olszewski, Jon E. Arnason, Inhye E. Ahn, Jennifer R. Brown
Journal: Blood
Blood (2024) 144 (Supplement 1): 1865.
https://doi.org/10.1182/blood-2024-206556
Published: 2024
Journal Articles

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Christine E. Ryan, Benjamin L. Lampson, Svitlana Tyekucheva, Liam R. Hackett, Yue Ren, Samantha J. Shupe, Stacey M. Fernandes, Jennifer L. Crombie, Samuel Ng, Austin I. Kim, Inhye E. Ahn, Matthew J Weinstock, Samantha Pazienza, Josie S. Montegaard, Victoria Patterson, Caron A. Jacobson, Ann S. LaCasce, Philippe Armand, David C. Fisher, Jon E. Arnason, Steve Lo, Adam Olszewski, Jennifer R. Brown, Matthew S. Davids
Journal: Blood
Blood (2022) 140 (Supplement 1): 837–838.
https://doi.org/10.1182/blood-2022-168003
Published: 2022